USA - July 16 2012
Two recent Delaware cases remind us of important provisions in confidentiality agreements entered into in connection with potential acquisitions.
Yelena M. Barychev, Christin R. Cerullo, Molly Crane, Melissa Palat Murawsky, Michael E. Plunkett
USA - October 31 2011
The SEC’s Division of Corporation Finance recently issued “CF Disclosure Guidance: Topic No. 1” summarizing the Division’s frequent comments on Form 8-K reports fi led by shell companies (i.e. a SEC registered reporting company that has no or nominal operations and assets (excluding cash and cash equivalents)) to report reverse mergers and similar transactions by which they cease to be shell companies.
Yelena M. Barychev, Christin R. Cerullo, Melissa Palat Murawsky, Michael E. Plunkett
USA - June 21 2013
On May 7, 2013, the Public Company Accounting Oversight Board (PCAOB) reproposed an auditing standard, Related Parties, as well as amendments to…
Yelena M. Barychev, Melissa Palat Murawsky, Michael E. Plunkett
USA - January 30 2012
In a case that should serve as a warning to the owners, directors and officers of privately-held companies that offer equity plans to their employees, on December 12, 2011, the SEC filed suit against Stiefel Laboratories, Inc. (at the time of the alleged misconduct, the world’s largest privately held manufacturer of dermatology products and now a subsidiary of GlaxoSmithKline PLC) and Charles Stiefel, the then controlling shareholder, chairman and CEO.
Yelena M. Barychev, Christin R. Cerullo, Melissa Palat Murawsky, Michael E. Plunkett
USA - January 24 2013
On December 19, 2012, the SEC announced that the Notice required by the Iran Threat Reduction and Syria Human Rights Act of 2012 should be filed on…
Yelena M. Barychev, Molly Crane, Melissa Palat Murawsky, Michael E. Plunkett